BCDA (BioCardia) 5-Year EBITDA Growth Rate: 41.30% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCDA BioCardia Inc BCDA
25 GF Score
Price $0.95
! 1 Warning Sign
View Full Analysis

What is BioCardia 5-Year EBITDA Growth Rate?

BioCardia BCDA -0.53% 25 5-Year EBITDA Growth Rate is 41.30% as of Mar. 2026. GuruFocus rates BCDA with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

BioCardia's EBITDA per Share for the three months ended in Mar. 2026 was $-0.21.

During the past 3 years, the average EBITDA Per Share Growth Rate was 50.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 41.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BioCardia was 61.60% per year. The lowest was -72.40% per year. And the median was 36.20% per year.

BioCardia  (NAS:BCDA) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

BioCardia 5-Year EBITDA Growth Rate Related Terms

BCDA vs SNTI, COCP, ZEOX: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, BioCardia's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCardia 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where BioCardia's 5-Year EBITDA Growth Rate falls into.


BCDA
25GF Score
BioCardia Inc BCDA
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCardia 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 41.30% mean?
BioCardia (BCDA) has a 5-Year EBITDA Growth Rate of 41.30% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for BioCardia and its competitors.
Is BioCardia's 5-Year EBITDA Growth Rate too high?
BioCardia's current 5-Year EBITDA Growth Rate is 41.30%. Overall, BioCardia has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does BioCardia's 5-Year EBITDA Growth Rate compare to SNTI and COCP?
BioCardia's 5-Year EBITDA Growth Rate of 41.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for BioCardia and its competitors. BioCardia's current 5-Year EBITDA Growth Rate is 41.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCardia stock overvalued right now?
BioCardia (BCDA) has a current 5-Year EBITDA Growth Rate of 41.30%. The current 5-Year EBITDA Growth Rate is 41.30%. BioCardia's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For BioCardia (BCDA), the current 5-Year EBITDA Growth Rate is 41.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioCardia Business Description

Address 320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
25GF Score

Get the complete analysis for BCDA

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.95
Price